环磷酰胺与他克莫司治疗男性肾病综合征的效果比较

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Cyclophosphamide and Tacrolimus in the treatment of male nephrotic syndrome.Methods Seventy male patients with nephrotic syndrome admitted to our hospital from February 2017 to December 2018 were selected as subjects,they were divided into group A and group B according to the random number table method,with 35 cases in each group.Group A was given hormone combined with Tacrolimus,and group B was given hormone combined with Cyclophosphamide.Both groups were treated for 3 months,serum albumin levels,24 h urine protein ration and serum sex hormone levels were compared between the two groups before and 3 months after treatment.Results After 3 months of treatment,the 24 hour urine protein ration of group A was lower than that of group B,the serum albumin level was higher than that in group B,the differences were statistically significant (P＜0.05).Before treatment,there were no significant differences between the two groups in hormone levels (P＞0.05).At 3 months after treatment,the levels of estradiol (E2) and testosterone (T) in the two groups were lower than those before treatment,with statistically significant differences (P＜0.05).At 3 months after treatment,follicle-stimulating hormone (FSH) and luteinizing levels in group A were higher than those before treatment,with statistically significant differences (P＜0.05).At 3 months after treatment,E2 and T levels in group A were higher than those in group B,while FSH level was lower than that in group B,with statistically significant differences (P＜0.05).Conclusion Compared with Cyclophosphamide,Tacrolimus combined with hormone therapy has better curative effect on male nephrotic syndrome,and has less influence on serum sex hormones,which is suitable for clinical application.

Key words： Cyclophosphamide Tacrolimus Nephrotic syndrome Sex hormone

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Yu
	SUN Xiao-mei

Cite this article:

WU Yu,SUN Xiao-mei. Comparison of the effects of Cyclophosphamide and Tacrolimus in the treatment of male nephrotic syndrome[J]. 中国当代医药, 2020, 27(1): 99-101.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I1/99

[1]	郝静，袁伟杰.难治性肾病综合征的病因及治疗研究进展[J].中国中西医结合肾病杂志，2013，14（6）：553-555.
[2]	王俊，邓旭，徐梅昌.原发性肾病综合征激素治疗前后证候演变规律的研究[J].浙江中医药大学学报，2016，40（9）：669-676.
[3]	郑方芳，陈丽植，姜梦婕.单中心激素耐药型肾病综合征患儿基因突变临床分析[J].中华实用儿科临床杂志，2018，33（12）：923-927.
[4]	袁锦，朱再志，许志忠，等.环磷酰胺联合激素治疗成人复发性微小病变肾病综合征疗效观察[J].四川医学，2015，36（8）：1138-1140.
[5]	刘干炎，陈帮明，刘永芳，等.他克莫司治疗老年激素抵抗型肾病综合征的临床效果[J].中国当代医药，2016，23（33）：132-134.
[6]	中华中医药学会肾病分会.原发性肾病综合征的诊断、辨证分型及疗效评定（试行方案）[J].上海中医药杂志,40（10）：51-52.
[7]	苏海霞，覃远汉.儿童难治性肾病治疗进展[J].实用医学杂志，2016，32（23）：3968-3970.
[8]	陈吉林.糖皮质激素抵抗在特发性肾病综合征中的研究进展[J].国际泌尿系统杂志，2014，34（1）：122-128.
[9]	蔡广研.特发性膜性肾病的诊治进展[J].北京医学，2012，34（4）：246-247.
[10]	李夏玉，陈江华.难治性肾病综合征的免疫抑制治疗[J].临床肾脏病杂志，2012，12（3）：100-101.
[11]	张继东，贾宁，刘楷东，等.环磷酰胺的肝细胞损伤作用机制研究[J].中国药物与临床，2016，16（11）：1664-1667.
[12]	林琦，魏蔚霞，王庆文，等.环磷酰胺治疗系统性红斑狼疮的卵巢毒性及防治[J].中国医药导报，2014，11（11）：165-166.
[13]	吴晓明，何威，高远赋.他克莫司治疗儿童难治性肾病综合征191 例[J].中华实用儿科临床杂志，2015，30（5）：342-345.
[14]	陈超阳，盛晓燕，周颖.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床观察[J].哈尔滨医科大学学报，2015，49（5）：446-449.
[15]	叶琨，王浩宇，徐珏，等.他克莫司联合糖皮质激素治疗难治性肾病综合征的临床评估[J].实用医学杂志，2013，29（9）：1500-1502.
[16]	侯凡凡.IgA 肾病的治疗-KDIGO 临床指南[C]//广东省中医药学会、中西医结合学会肾病专业委员会学术年会.2010.